Tulipano Stephen J 4
4 · Stoke Therapeutics, Inc. · Filed Feb 24, 2021
Insider Transaction Report
Form 4
Transactions
- Sale
Common Stock
2021-02-22$58.67/sh−15,202$891,942→ 10,400 total - Sale
Common Stock
2021-02-22$60.00/sh−102$6,120→ 602 total - Sale
Common Stock
2021-02-23$58.60/sh−5,000$292,992→ 602 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2021-02-23−5,000→ 179,997 totalExercise: $4.48Exp: 2029-03-18→ Common Stock (5,000 underlying) - Exercise/Conversion
Employee Stock Option (Right to Buy)
2021-02-22−25,000→ 184,997 totalExercise: $4.48Exp: 2029-03-18→ Common Stock (25,000 underlying) - Exercise/Conversion
Common Stock
2021-02-22$4.48/sh+25,000$112,000→ 25,602 total - Sale
Common Stock
2021-02-22$59.29/sh−9,696$574,842→ 704 total - Exercise/Conversion
Common Stock
2021-02-23$4.48/sh+5,000$22,400→ 5,602 total
Footnotes (4)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.00 to $58.99 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.00 to $59.96 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The option vested as to 1/4th of the total shares on March 15, 2020, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.